PharmacoEconomics (2018) 36:731–732 https://doi.org/10.1007/s40273-018-0666-x EDITORIAL Should Low- and Middle-Income Countries Adopt Clinical Guidelines Developed in ‘Rich’ Countries? Alan Haycox Published online: 7 June 2018 Springer International Publishing AG, part of Springer Nature 2018 I always ﬁnd conferences where the latest clinical guide- relevance, clinical guidelines must explicitly take account lines are presented incredibly informative. The reaction of of the limited resources available to many LMICs whether the audience immediately enables me to distinguish clini- in terms of medical technology or new and expensive cians that practice in rich countries from those that practice drugs. Since 2010, a total of 139 new medicines have been in low- and middle-income countries (LMICs). Clinicians registered by the European Union and many of these ‘in- from the rich countries listen with rapt attention to ascer- novations’ were rapidly incorporated into new clinical tain how best this guideline can be incorporated into their guidelines. However, out of this total, Bulgaria publicly clinical practice. In contrast, clinicians from LMICs appear reimbursed only 44, Croatia reimbursed 27 whilst Serbia to be far less interested and perhaps even dismissive of the reimbursed only 1! . Clearly, for a clinical guideline to presentation. Such a variation in response
PharmacoEconomics – Springer Journals
Published: Jun 7, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera